Rinvoq vs Cosentyx
A side-by-side look at two autoimmune medications advertised on TV. Informational only — not medical advice.
| US Rinvoq | US Cosentyx | |
|---|---|---|
| Generic name | upadacitinib | secukinumab |
| Drug class | JAK Inhibitor | IL-17A Inhibitor (Biologic) |
| Treats | Rheumatoid arthritis, psoriatic arthritis, eczema | Plaque psoriasis, psoriatic arthritis, ankylosing spondylitis |
| Category | Autoimmune | Autoimmune |
| Manufacturer | AbbVie | Novartis |
| Year approved | 2019 | 2015 |
| FDA warning | Black box warning | Moderate warnings |
| Est. TV ad spend | $175M | $160M |
| Common side effects | Serious infections, Blood clots, Cardiovascular events, Cancer risk | Respiratory infections, Inflammatory bowel disease, Fungal infections, Injection site reactions |
Frequently asked questions
Is Rinvoq or Cosentyx better?
Neither is universally "better." Rinvoq (upadacitinib) and Cosentyx (secukinumab) are both used for autoimmune, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Rinvoq and Cosentyx?
Rinvoq is a JAK Inhibitor made by AbbVie, while Cosentyx is a IL-17A Inhibitor (Biologic) made by Novartis. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Rinvoq has the larger estimated TV advertising budget of the two.